All Stories

  1. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  2. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  3. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  4. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  5. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  6. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  7. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  8. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  9. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  10. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  11. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  12. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  13. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  14. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  15. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  16. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  17. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  18. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  19. Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
  20. Genetic analyses across cardiovascular traits: leveraging genetic correlations to empower locus discovery and prediction in common cardiovascular diseases
  21. Impact of clonal hematopoiesis on cardiovascular outcomes in cancer patients of the UK Biobank
  22. Effect of probiotic supplementation on glycemic control in patients with type 2 diabetes: A randomized controlled trial
  23. Investigating the effects of a randomized, double-blinded aerobic, resistance, and cognitive training clinical trial on neurocognitive function in older adults with cardiovascular risk factors: the ACTIONcardioRisk protocol
  24. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
  25. A genome-wide study of the effect of alcohol consumption on the risk of type 2 diabetes
  26. Disentangling the effects of sex and gender on APOE ɛ4–related neurocognitive impairment
  27. RISK SCORE FOR FUTURE MYOCARDIAL INFARCTION AFTER AN ACUTE CORONARY SYNDROME AND PHARMACOGENETIC RESPONSE TO DALCETRAPIB
  28. Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes
  29. GWAS of CRP response to statins further supports the role of APOE in statin response: A GIST consortium study
  30. A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress
  31. Accountability for Reasonableness as a Framework for the Promotion of Fair and Equitable Research
  32. Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy
  33. The Relationship Between Perceived Parenting Practices and Anxiety in Adults With Congenital Heart Disease
  34. The role of genetically predicted serum iron levels on neurodegenerative and cardiovascular traits
  35. Reduction of clonal hematopoiesis mutation burden in coronary patients treated with low-dose colchicine
  36. Pharmacogenomics of CRP response to statins: a GIST consortium study
  37. Plasma statin concentrations do not correlate with statin-induced myalgia
  38. Data from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  39. Supplementary Figure 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  40. Supplementary Figure 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  41. Supplementary Figure 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  42. Supplementary Figure 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  43. Supplementary Table 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  44. Supplementary Table 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  45. Supplementary Table 10 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  46. Supplementary Table 10 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  47. Supplementary Table 11 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  48. Supplementary Table 11 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  49. Supplementary Table 12 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  50. Supplementary Table 12 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  51. Supplementary Table 13 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  52. Supplementary Table 13 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  53. Supplementary Table 14 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  54. Supplementary Table 14 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  55. Supplementary Table 15 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  56. Supplementary Table 15 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  57. Supplementary Table 16 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  58. Supplementary Table 16 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  59. Supplementary Table 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  60. Supplementary Table 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  61. Supplementary Table 3 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  62. Supplementary Table 3 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  63. Supplementary Table 4 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  64. Supplementary Table 4 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  65. Supplementary Table 5 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  66. Supplementary Table 5 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  67. Supplementary Table 6 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  68. Supplementary Table 6 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  69. Supplementary Table 7 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  70. Supplementary Table 7 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  71. Supplementary Table 8 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  72. Supplementary Table 8 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  73. Supplementary Table 9 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  74. Supplementary Table 9 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  75. Prediction of incident atrial fibrillation using deep learning, clinical models, and polygenic scores
  76. A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol
  77. Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias
  78. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  79. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  80. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  81. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  82. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  83. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  84. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  85. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  86. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  87. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  88. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  89. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  90. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  91. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  92. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  93. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  94. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  95. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  96. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  97. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  98. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  99. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  100. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  101. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  102. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  103. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  104. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  105. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  106. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  107. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  108. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  109. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  110. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  111. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  112. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  113. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  114. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  115. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  116. A Genomewide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol
  117. Childhood Maltreatment and Leukocyte Telomere Length: Cardiac Vagal Activity Influences the Relation in Older Adults
  118. A dataset of proteomic changes during human heat stress and heat acclimation
  119. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  120. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  121. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  122. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  123. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  124. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  125. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  126. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  127. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  128. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  129. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  130. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  131. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  132. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  133. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  134. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  135. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  136. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  137. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  138. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  139. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  140. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  141. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  142. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  143. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  144. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  145. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  146. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  147. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  148. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  149. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  150. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  151. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  152. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  153. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  154. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  155. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  156. T46. DO SEX AND GENDER MODIFY THE EFFECT OF APOE-Ɛ4 ON NEUROCOGNITIVE IMPAIRMENT? A MULTI-ANCESTRY ANALYSIS IN THE UK BIOBANK
  157. Impact of amiodarone use on metoprolol concentrations, α‐OH‐metoprolol concentrations, metoprolol dosing and heart rate: A cross‐sectional study
  158. Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8,089 patients
  159. The Influence of Illness Perception and Coping on Anxiety in Adults With Congenital Heart Disease
  160. Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals
  161. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  162. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  163. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  164. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  165. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  166. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  167. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  168. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  169. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  170. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  171. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  172. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  173. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  174. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  175. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  176. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  177. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  178. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  179. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  180. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  181. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  182. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  183. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  184. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  185. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  186. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  187. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  188. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  189. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  190. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  191. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  192. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  193. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  194. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  195. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  196. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  197. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  198. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  199. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  200. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  201. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  202. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  203. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  204. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  205. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  206. Pharmacogenomic Markers of Metoprolol and α-OH-Metoprolol Concentrations: A Genome-Wide Association Study
  207. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  208. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  209. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  210. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  211. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  212. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  213. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  214. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  215. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  216. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  217. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  218. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  219. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  220. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  221. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  222. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  223. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  224. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  225. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  226. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  227. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  228. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  229. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  230. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  231. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  232. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  233. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  234. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  235. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  236. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  237. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  238. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  239. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  240. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  241. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  242. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  243. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  244. Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  245. Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
  246. Study of effect modifiers of genetically predicted CETP reduction
  247. Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia
  248. Childhood maltreatment and leukocyte telomere length in men and women with chronic illness: an evaluation of moderating and mediating influences
  249. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
  250. Abstract 10075: Hematopoietic Mosaic Chromosomal Alterations and Cardiovascular Disease-Related Deaths Among Cancer Survivors: An Analysis of the UK Biobank
  251. Erratum to: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
  252. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies
  253. Do variants in the coding regions of FOXP2, a gene implicated in speech disorder, confer a risk for congenital amusia?
  254. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
  255. Including diverse and admixed populations in genetic epidemiology research
  256. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
  257. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
  258. Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease
  259. Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signalling involved in atheroprotection
  260. ExPheWas: a platform for cis -Mendelian randomization and gene-based association scans
  261. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
  262. Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study
  263. Gender matters in heart attack prevention: higher femininity linked to angina diagnosis in men
  264. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
  265. Quantitative Trait of Neutrophil Count Is Influenced By Variants in the Region of Gsdma and PSMD3-CSF3, aging, Cardiometabolic Comorbidities but Not By Chip
  266. Study of effect modifiers of genetically predicted CETP reduction
  267. A sex-specific evolutionary interaction between ADCY9 and CETP
  268. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
  269. Study of effect modifiers of genetically predicted CETP reduction
  270. Author response: A sex-specific evolutionary interaction between ADCY9 and CETP
  271. The genomics of heart failure: design and rationale of the HERMES consortium
  272. Multitrait GWAS to connect disease variants and biological mechanisms
  273. Comprehensive genetic analysis of the human lipidome identifies novel loci controlling lipid homeostasis with links to coronary artery disease
  274. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
  275. Genetics of symptom remission in outpatients with COVID-19
  276. A sex-specific evolutionary interaction betweenADCY9andCETP
  277. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  278. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
  279. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
  280. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
  281. ExPheWas: a browser for gene-based pheWAS associations
  282. Genetics of symptom remission in outpatients with COVID-19
  283. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
  284. Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
  285. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
  286. The associations of hostility and defensiveness with telomere length are influenced by sex and health status
  287. A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
  288. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  289. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
  290. Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada
  291. A genetic model of ivabradine recapitulates results from randomized clinical trials
  292. Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms
  293. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential
  294. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  295. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis
  296. Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study
  297. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial
  298. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
  299. A genetic model of ivabradine recapitulates results from randomized clinical trials
  300. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
  301. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
  302. Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response
  303. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
  304. rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B
  305. Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expressionin vivothat correlates with increased antibody immune response
  306. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  307. Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
  308. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
  309. Subsequent Event Risk in Individuals With Established Coronary Heart Disease
  310. Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
  311. LONG-TERM RESIDUAL RISK AND PREDICTORS OF CARDIOVASCULAR DISEASE IN INDIVIDUALS TAKING STATINS FOR PRIMARY PREVENTION: INSIGHTS FROM THE CARTAGENE STUDY
  312. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
  313. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians
  314. Biomarkers of dementia in obstructive sleep apnea
  315. ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein)
  316. Pharmacogenetic content of commercial genome-wide genotyping arrays
  317. Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype
  318. Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
  319. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
  320. Protein-Coding Variants Implicate Novel Genes Related to Lipid Homeostasis Contributing to Body Fat Distribution
  321. Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines
  322. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study
  323. A Discrete Event Simulation Model For A Pharmacogenomics Test For Statin-Induced Myopathy In Patients Initiating A Statin In Secondary Cardiovascular Prevention
  324. Abstract 624: Interactions Between Adenylate Cyclase Type 9 (ADCY9) and Cholesteryl Ester Transfer Protein (CETP) in Atherosclerosis
  325. Pharmacogenomics of blood lipid regulation
  326. A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure
  327. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
  328. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  329. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  330. Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
  331. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  332. Polygenic determinants in extremes of high-density lipoprotein cholesterol
  333. ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels
  334. Exome-wide association study of plasma lipids in >300,000 individuals
  335. Precision medicine to change the landscape of cardiovascular drug development
  336. Impact of Selection Bias on Estimation of Subsequent Event Risk
  337. Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent
  338. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies
  339. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
  340. CKing Precision in the Interpretation of Diagnostic Biomarkers
  341. Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies
  342. Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve
  343. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
  344. Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol
  345. CETP
  346. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
  347. Whole Exome Sequencing of Affected Individuals From Large Consanguineous Pedigrees With Psychotic/Affective Disorders From Pakistan
  348. Pharmacogenomic approaches to lipid-regulating trials
  349. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
  350. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality
  351. Risk of Mortality and Hospital Readmission Among Older Adults with Heart Failure Treated with Carvedilol, Bisoprolol or Metoprolol Tartrate
  352. Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals
  353. A model to assess the cost–effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine
  354. Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
  355. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
  356. genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools
  357. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
  358. CYP3A4 Genotype is Associated with Sildenafil Concentrations in Patients with Heart Failure with Preserved Ejection Fraction
  359. Whole-genome sequencing in French Canadians from Quebec
  360. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
  361. Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals
  362. DNA methylation signature of human fetal alcohol spectrum disorder
  363. Avoidance of Vitamin K−Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes
  364. Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users
  365. Methylomic changes during conversion to psychosis
  366. Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease
  367. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials
  368. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance
  369. Testing the role of predicted gene knockouts in human anthropometric trait variation
  370. Resting heart rate as a predictor of aortic valve stenosis progression
  371. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
  372. Calcium Signaling Pathway GenesRUNX2andCACNA1CAre Associated With Calcific Aortic Valve DiseaseCLINICAL PERSPECTIVE
  373. ISDN2014_0418: DNA methylation changes in fetal alcohol spectrum disorder
  374. Association of Treatment with Carvedilol, Bisoprolol and Metoprolol on the Risk of Mortality and Hospital Admission Among Older Adults with Heart Failure
  375. Impact of Genetic Factors on Gastrointestinal Bleeding in a Prospective Cohort of new Warfarin users
  376. Will personalized drugs for cardiovascular disease become an option? – Defining ‘Evidence-based personalized medicine’ for its implementation and future use
  377. Impact of regular physical activity on weekly warfarin dose requirement
  378. A Pharmacogenetic Investigation of Intravenous Furosemide in Decompensated Heart Failure: A Meta-Analysis of 3 Clinical Trials
  379. Mutation Burden of Rare Variants in Schizophrenia Candidate Genes
  380. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review
  381. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
  382. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
  383. Comparison of Sequencing Based CNV Discovery Methods Using Monozygotic Twin Quartets
  384. CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase
  385. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
  386. G.P.197
  387. Genetic Markers of Cisplatin-Induced Hearing Loss in Children
  388. Modifiers of (CAG)n instability in Machado–Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes
  389. Development of a broad-based ADME panel for use in pharmacogenomic studies
  390. Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis
  391. Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer’s Disease
  392. The Use Of Pillbox And Time In Therapeutic Range Among New Users Of Warfarin: A Propective Cohort Study
  393. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits
  394. Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease
  395. Comparison of genotype clustering tools with rare variants
  396. Cuckoo search epistasis: a new method for exploring significant genetic interactions
  397. Validation of patient-reported warfarin dose in a prospective incident cohort study
  398. Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans
  399. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
  400. Validity of Self-Reported Dose of Patients Using Wafarin in Clinical Practice
  401. Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort
  402. pyGenClean: efficient tool for genetic data clean up before association testing
  403. Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  404. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
  405. Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
  406. The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans
  407. Institutional Profile: The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute
  408. SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa
  409. Characterization of two novel cold-inducible K3 dehydrin genes from alfalfa (Medicago sativa spp. sativa L.)
  410. Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians
  411. G.P.126 “Strongman syndrome”: A new autosomal dominant herculean painful myopathy
  412. Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease
  413. Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice
  414. Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol
  415. Assessment of Genetic Variability of Cell Wall Degradability for the Selection of Alfalfa with Improved Saccharification Efficiency
  416. PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients
  417. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
  418. Molecular physiology and breeding at the crossroads of cold hardiness improvement
  419. Risk of congenital heart defects is influenced by genetic variation in folate metabolism
  420. A Novel PLP1 Mutation Further Expands the Clinical Heterogeneity at the Locus
  421. Erratum to: Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  422. Validation of warfarin pharmacogenetic algorithms in clinical practice
  423. Tacrolimus-induced nephrotoxicity and genetic variability: A review
  424. Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  425. Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec
  426. Predicting Statin Induced Muscle Toxicity
  427. Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes
  428. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors
  429. Familial ventricular aneurysms and septal defects map to chromosome 10p15
  430. Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1
  431. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
  432. Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts
  433. Partitioning of copy-number genotypes in pedigrees
  434. Family Study of Restless Legs Syndrome in Quebec, Canada
  435. Mutations in DCC Cause Congenital Mirror Movements
  436. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia
  437. Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are…
  438. Genetics of bronchopulmonary dysplasia in the age of genomics
  439. Testing for Gene-Gene Interaction with AMMI Models
  440. Novel mutations in the sacsin gene in ataxia patients from Maritime Canada
  441. Genome-Wide TDT Analysis in French-Canadian Families with Tourette Syndrome
  442. Genetic Studies
  443. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  444. Genetic Modulation of Brugada Syndrome by a Common Polymorphism
  445. Application of principal component analysis to pharmacogenomic studies in Canada
  446. Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel
  447. Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2
  448. Application of Homozygosity Haplotype Analysis to Genetic Mapping with High-Density SNP Genotype Data
  449. Genetic predictors of depressive symptoms in cardiac patients
  450. The challenge of detecting epistasis (G×G Interactions): Genetic Analysis Workshop 16
  451. Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1
  452. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform – from R&D to the clinic
  453. Mutations in the calcium-related gene IL1RAPL1 are associated with autism
  454. CYP3A5*1/*3 Genetic Polymorphism Is Associated with Post Cardiac Transplant Renal Dysfunction in Patients Treated with Calcineurin Inhibitors
  455. A survey of the personalized medicine landscape
  456. Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
  457. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
  458. A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11
  459. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans
  460. The Genetics of Congenital Amusia (Tone Deafness): A Family-Aggregation Study
  461. Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy
  462. Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain
  463. Obesity and TCF7L2 variants' additive effect on type 2 diabetes risk in cardiac patients
  464. Molecular genetic studies of DMT1 on 12q in French‐Canadian restless legs syndrome patients and families
  465. Loss-of-function genetic diseases and the concept of pharmaceutical targets
  466. Gene-Gene Interaction Tests Using SVM and Neural Network Modeling
  467. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
  468. Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans
  469. Multistage designs in the genomic era: Providing balance in complex disease studies
  470. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13
  471. Bootstrap Inference with Neural-Network Modeling for Gene-Disease Association Testing
  472. A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3
  473. Human monogenic disorders — a source of novel drug targets
  474. Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin
  475. Autism spectrum disorders associated with X chromosome markers in French-Canadian males
  476. A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors
  477. Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region
  478. Chromosome 11-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population
  479. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
  480. The 14q restless legs syndrome locus in the French Canadian population
  481. Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates
  482. Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
  483. A Study of Discontinuing Maintenance Therapy in Human Immunodeficiency Virus–Infected Subjects with DisseminatedMycobacterium aviumComplex: AIDS Clinical Trial Group 393 Study Team
  484. AnALS2gene mutation causes hereditary spastic paraplegia in a Pakistani kindred
  485. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy
  486. Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population
  487. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
  488. Clouston hidrotic ectodermal dysplasia (HED): genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping
  489. A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment ofMycobacterium aviumComplex Bacteremia with Clarithromycin‐Based Combination Therapy
  490. Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3
  491. Protease inhibitor-associated hyperglycaemia
  492. Prophylaxis against DisseminatedMycobacterium aviumComplex with Weekly Azithromycin, Daily Rifabutin, or Both
  493. Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease
  494. Panculture Panned
  495. How Useful Are Cytomegalovirus Cultures in Patients with HIV Infection?
  496. Prevention and treatment of opportunistic infections
  497. Tuberculous meningitis in patients with and without human immunodeficiency virus infection